A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016 View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-12

AUTHORS

Comfort Kunak Ogar, Abiodun Abiola, Daniel Yuah, Ali Ibrahim, Ibrahim Adekunle Oreagba, Emmanuel C. Amadi, Mojisola Christianah Adeyeye, Kazeem Adeola Oshikoya

ABSTRACT

Adverse drug reactions (ADRs) are a source of concern in healthcare as they negatively affect patients. Serious adverse drug reactions (SADRs) have an even greater impact on patients and the system in terms of morbidity and financial burden. The establishment of National Pharmacovigilance Centers (NPCs) has enhanced ADR reporting in Africa. The Nigerian Pharmacovigilance Centre has been collecting ADR reports using VigiFlow since 2004. The aim of this study was to identify and analyze SADR reports in the Nigerian VigiFlow database in order to profile the patients with SADRs, the medicines most implicated, system organ classes (SOCs) affected, outcome of such reactions, including fatalities, and ADR reporting trends over the years. We also looked at the data elements provided in the reports as a proxy measure of report quality. We retrospectively assessed all individual case safety reports (ICSRs) received by the NPC in Nigeria and entered into VigiFlow as SADR reports between September 2004 and December 2016. We defined SADR as any untoward reaction to any medicine dose that resulted in death, required in-patient hospitalization or prolongation of existing hospitalization, resulted in congenital anomaly, persistent or significant disability/incapacity or was life-threatening. The suspected SADRs were analyzed at the Medical Dictionary for Regulatory Activities SOC and Preferred Term levels. A total of 11,222 ICSRs were entered into VigiFlow during the study period, of which 298 (3%) were classified as SADR reports. Adults were the most affected (244/282; 87%). The median number of medicines per report was 3 (interquartile range = 2–4.75). Nevirapine (36/336; 11%), as a single entity, was the most reported medicine. Human immunodeficiency virus (HIV) infection affected 128/232 (55%) of those with SADRs. There was no statistically significant association between the number of reactions per report and sex of the patients (p = 0.280), their age groups (p = 0.670), or the number of medicines per report (p = 0.640). Hospitalization was the most frequently cited reason for classifying a report as serious (151/276; 53%) and death was reported in 48 cases (48/283; 17%). Based on the SOC, skin and subcutaneous tissue disorders (139/550; 25%) was the most affected, while anemia (55/550; 10%) was the most reported specific reaction. A substantial number of patients (107/256; 42%) either recovered fully or were recovering from the SADRs. The number of SADR reports received varied by year with no consistent trend. There is under-reporting of ADRs in the Nigerian VigiFlow® database, particularly SADRs and those involving pediatric and geriatric age groups. Given that over half of the SADR reports involved antiretroviral drugs, it is imperative to increase the surveillance of ADRs related to this class of drugs through regular clinical assessment of reports and provision of feedback on the findings to healthcare providers. Direct consumer reporting should also be encouraged as a means of increasing ADR reporting. More... »

PAGES

1-13

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40290-019-00267-2

DOI

http://dx.doi.org/10.1007/s40290-019-00267-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112703658


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ogar", 
        "givenName": "Comfort Kunak", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abiola", 
        "givenName": "Abiodun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuah", 
        "givenName": "Daniel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ibrahim", 
        "givenName": "Ali", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Lagos", 
          "id": "https://www.grid.ac/institutes/grid.411782.9", 
          "name": [
            "University of Lagos, Lagos, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oreagba", 
        "givenName": "Ibrahim Adekunle", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amadi", 
        "givenName": "Emmanuel C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adeyeye", 
        "givenName": "Mojisola Christianah", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lagos State University", 
          "id": "https://www.grid.ac/institutes/grid.411276.7", 
          "name": [
            "Pharmacology, Therapeutic and Toxicology Department, Lagos State University College of Medicine, Lagos, Nigeria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oshikoya", 
        "givenName": "Kazeem Adeola", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3233/jrs-160669", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003989029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0004439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010384750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-200629050-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012106416", 
          "https://doi.org/10.2165/00002018-200629050-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.279.15.1200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018359649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/2229-3485.111784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020050873"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03262002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021544500", 
          "https://doi.org/10.1007/bf03262002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2325957414557264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023283344"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2325957414557264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023283344"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/20469047.2015.1122384", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025047465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02799-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026617336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjopharm.2006.03.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027174345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4314/gmj.v48i4.5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034395355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4314/gmj.v48i4.5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034395355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2007.02993.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037610415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.phrs.2006.05.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038037726"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-200932010-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042490964", 
          "https://doi.org/10.2165/00002018-200932010-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/0253-7613.150344", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045701194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bjo.77.5.315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046282706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1472-6904-9-14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047421326", 
          "https://doi.org/10.1186/1472-6904-9-14"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/2229-3485.192044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047448481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/0976-500x.162004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050192219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4172/2167-0870.1000155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051379799"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4102/sajhivmed.v16i1.305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072231303"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-114-4-297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073695304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074794042", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077250542", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/prp2.297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083825048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/prp2.297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083825048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18203/2320-6012.ijrms20180310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100663071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18203/2320-6012.ijrms20180310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100663071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0228-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101363171", 
          "https://doi.org/10.1007/s40290-018-0228-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0228-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101363171", 
          "https://doi.org/10.1007/s40290-018-0228-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0228-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101363171", 
          "https://doi.org/10.1007/s40290-018-0228-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0228-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101363171", 
          "https://doi.org/10.1007/s40290-018-0228-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0253-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109992161", 
          "https://doi.org/10.1007/s40290-018-0253-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0253-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109992161", 
          "https://doi.org/10.1007/s40290-018-0253-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0253-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109992161", 
          "https://doi.org/10.1007/s40290-018-0253-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40290-018-0253-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109992161", 
          "https://doi.org/10.1007/s40290-018-0253-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-12", 
    "datePublishedReg": "2019-03-12", 
    "description": "Adverse drug reactions (ADRs) are a source of concern in healthcare as they negatively affect patients. Serious adverse drug reactions (SADRs) have an even greater impact on patients and the system in terms of morbidity and financial burden. The establishment of National Pharmacovigilance Centers (NPCs) has enhanced ADR reporting in Africa. The Nigerian Pharmacovigilance Centre has been collecting ADR reports using VigiFlow since 2004. The aim of this study was to identify and analyze SADR reports in the Nigerian VigiFlow database in order to profile the patients with SADRs, the medicines most implicated, system organ classes (SOCs) affected, outcome of such reactions, including fatalities, and ADR reporting trends over the years. We also looked at the data elements provided in the reports as a proxy measure of report quality. We retrospectively assessed all individual case safety reports (ICSRs) received by the NPC in Nigeria and entered into VigiFlow as SADR reports between September 2004 and December 2016. We defined SADR as any untoward reaction to any medicine dose that resulted in death, required in-patient hospitalization or prolongation of existing hospitalization, resulted in congenital anomaly, persistent or significant disability/incapacity or was life-threatening. The suspected SADRs were analyzed at the Medical Dictionary for Regulatory Activities SOC and Preferred Term levels. A total of 11,222 ICSRs were entered into VigiFlow during the study period, of which 298 (3%) were classified as SADR reports. Adults were the most affected (244/282; 87%). The median number of medicines per report was 3 (interquartile range = 2\u20134.75). Nevirapine (36/336; 11%), as a single entity, was the most reported medicine. Human immunodeficiency virus (HIV) infection affected 128/232 (55%) of those with SADRs. There was no statistically significant association between the number of reactions per report and sex of the patients (p = 0.280), their age groups (p = 0.670), or the number of medicines per report (p = 0.640). Hospitalization was the most frequently cited reason for classifying a report as serious (151/276; 53%) and death was reported in 48 cases (48/283; 17%). Based on the SOC, skin and subcutaneous tissue disorders (139/550; 25%) was the most affected, while anemia (55/550; 10%) was the most reported specific reaction. A substantial number of patients (107/256; 42%) either recovered fully or were recovering from the SADRs. The number of SADR reports received varied by year with no consistent trend. There is under-reporting of ADRs in the Nigerian VigiFlow\u00ae database, particularly SADRs and those involving pediatric and geriatric age groups. Given that over half of the SADR reports involved antiretroviral drugs, it is imperative to increase the surveillance of ADRs related to this class of drugs through regular clinical assessment of reports and provision of feedback on the findings to healthcare providers. Direct consumer reporting should also be encouraged as a means of increasing ADR reporting.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40290-019-00267-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1319803", 
        "issn": [
          "1178-2595", 
          "1179-1993"
        ], 
        "name": "Pharmaceutical Medicine", 
        "type": "Periodical"
      }
    ], 
    "name": "A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016", 
    "pagination": "1-13", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5df79008e151897a76f9458551def6bc0b63a6449933277725d0088026e3dfac"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40290-019-00267-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112703658"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40290-019-00267-2", 
      "https://app.dimensions.ai/details/publication/pub.1112703658"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000358_0000000358/records_127441_00000011.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40290-019-00267-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40290-019-00267-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40290-019-00267-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40290-019-00267-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40290-019-00267-2'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      21 PREDICATES      52 URIs      16 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40290-019-00267-2 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N47e6b79e5b66434d9b14129f142da236
4 schema:citation sg:pub.10.1007/bf03262002
5 sg:pub.10.1007/s40290-018-0228-8
6 sg:pub.10.1007/s40290-018-0253-7
7 sg:pub.10.1186/1472-6904-9-14
8 sg:pub.10.2165/00002018-200629050-00003
9 sg:pub.10.2165/00002018-200932010-00002
10 https://app.dimensions.ai/details/publication/pub.1074794042
11 https://app.dimensions.ai/details/publication/pub.1077250542
12 https://doi.org/10.1001/jama.279.15.1200
13 https://doi.org/10.1002/prp2.297
14 https://doi.org/10.1016/j.amjopharm.2006.03.002
15 https://doi.org/10.1016/j.phrs.2006.05.003
16 https://doi.org/10.1016/s0140-6736(00)02799-9
17 https://doi.org/10.1080/20469047.2015.1122384
18 https://doi.org/10.1111/j.1365-2125.2007.02993.x
19 https://doi.org/10.1136/bjo.77.5.315
20 https://doi.org/10.1177/2325957414557264
21 https://doi.org/10.1371/journal.pone.0004439
22 https://doi.org/10.18203/2320-6012.ijrms20180310
23 https://doi.org/10.3233/jrs-160669
24 https://doi.org/10.4102/sajhivmed.v16i1.305
25 https://doi.org/10.4103/0253-7613.150344
26 https://doi.org/10.4103/0976-500x.162004
27 https://doi.org/10.4103/2229-3485.111784
28 https://doi.org/10.4103/2229-3485.192044
29 https://doi.org/10.4172/2167-0870.1000155
30 https://doi.org/10.4314/gmj.v48i4.5
31 https://doi.org/10.7326/0003-4819-114-4-297
32 schema:datePublished 2019-03-12
33 schema:datePublishedReg 2019-03-12
34 schema:description Adverse drug reactions (ADRs) are a source of concern in healthcare as they negatively affect patients. Serious adverse drug reactions (SADRs) have an even greater impact on patients and the system in terms of morbidity and financial burden. The establishment of National Pharmacovigilance Centers (NPCs) has enhanced ADR reporting in Africa. The Nigerian Pharmacovigilance Centre has been collecting ADR reports using VigiFlow since 2004. The aim of this study was to identify and analyze SADR reports in the Nigerian VigiFlow database in order to profile the patients with SADRs, the medicines most implicated, system organ classes (SOCs) affected, outcome of such reactions, including fatalities, and ADR reporting trends over the years. We also looked at the data elements provided in the reports as a proxy measure of report quality. We retrospectively assessed all individual case safety reports (ICSRs) received by the NPC in Nigeria and entered into VigiFlow as SADR reports between September 2004 and December 2016. We defined SADR as any untoward reaction to any medicine dose that resulted in death, required in-patient hospitalization or prolongation of existing hospitalization, resulted in congenital anomaly, persistent or significant disability/incapacity or was life-threatening. The suspected SADRs were analyzed at the Medical Dictionary for Regulatory Activities SOC and Preferred Term levels. A total of 11,222 ICSRs were entered into VigiFlow during the study period, of which 298 (3%) were classified as SADR reports. Adults were the most affected (244/282; 87%). The median number of medicines per report was 3 (interquartile range = 2–4.75). Nevirapine (36/336; 11%), as a single entity, was the most reported medicine. Human immunodeficiency virus (HIV) infection affected 128/232 (55%) of those with SADRs. There was no statistically significant association between the number of reactions per report and sex of the patients (p = 0.280), their age groups (p = 0.670), or the number of medicines per report (p = 0.640). Hospitalization was the most frequently cited reason for classifying a report as serious (151/276; 53%) and death was reported in 48 cases (48/283; 17%). Based on the SOC, skin and subcutaneous tissue disorders (139/550; 25%) was the most affected, while anemia (55/550; 10%) was the most reported specific reaction. A substantial number of patients (107/256; 42%) either recovered fully or were recovering from the SADRs. The number of SADR reports received varied by year with no consistent trend. There is under-reporting of ADRs in the Nigerian VigiFlow® database, particularly SADRs and those involving pediatric and geriatric age groups. Given that over half of the SADR reports involved antiretroviral drugs, it is imperative to increase the surveillance of ADRs related to this class of drugs through regular clinical assessment of reports and provision of feedback on the findings to healthcare providers. Direct consumer reporting should also be encouraged as a means of increasing ADR reporting.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf sg:journal.1319803
39 schema:name A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016
40 schema:pagination 1-13
41 schema:productId N36f2c5aaa9634b5087a922a5a5894140
42 N43e139dd500d4e8ea98ca379ec8b56fd
43 N6177f8f4e20046dcb28b58cf046fcff6
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112703658
45 https://doi.org/10.1007/s40290-019-00267-2
46 schema:sdDatePublished 2019-04-11T11:41
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N37c4f5f8df75489dab90533d80ae103c
49 schema:url https://link.springer.com/10.1007%2Fs40290-019-00267-2
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N0a965e0dfe6e4cc9ae239bb23ae45fd5 schema:affiliation N0b6f958c71634ff08a98a06b5986eb15
54 schema:familyName Abiola
55 schema:givenName Abiodun
56 rdf:type schema:Person
57 N0b6f958c71634ff08a98a06b5986eb15 schema:name National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
58 rdf:type schema:Organization
59 N1935e24362034f7e8519c45a496342a3 schema:affiliation N20e602fbe93848a1a39e019a6acccdae
60 schema:familyName Yuah
61 schema:givenName Daniel
62 rdf:type schema:Person
63 N20e602fbe93848a1a39e019a6acccdae schema:name National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
64 rdf:type schema:Organization
65 N220f849199224d4d85cdcdea40acc422 rdf:first Nf41c0131b0f54a74b96fb3bceee46717
66 rdf:rest N8d6c20535e4c4263bd49b515d51d64f5
67 N242bb738184d4e7f85aadaacbd2248ee schema:affiliation https://www.grid.ac/institutes/grid.411276.7
68 schema:familyName Oshikoya
69 schema:givenName Kazeem Adeola
70 rdf:type schema:Person
71 N2743f016e6254e1796e23a59d551578d schema:name National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
72 rdf:type schema:Organization
73 N293b5ded07854d728c4eadbd35efa5f9 rdf:first N0a965e0dfe6e4cc9ae239bb23ae45fd5
74 rdf:rest N9a1583322c1245f5a287613c22329e91
75 N2fb8dc48daf244aba1c1a50d1ba91d28 rdf:first N3476d9d76bec40478429e423a93a8284
76 rdf:rest N220f849199224d4d85cdcdea40acc422
77 N3476d9d76bec40478429e423a93a8284 schema:affiliation https://www.grid.ac/institutes/grid.411782.9
78 schema:familyName Oreagba
79 schema:givenName Ibrahim Adekunle
80 rdf:type schema:Person
81 N36f2c5aaa9634b5087a922a5a5894140 schema:name doi
82 schema:value 10.1007/s40290-019-00267-2
83 rdf:type schema:PropertyValue
84 N37c4f5f8df75489dab90533d80ae103c schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 N43e139dd500d4e8ea98ca379ec8b56fd schema:name readcube_id
87 schema:value 5df79008e151897a76f9458551def6bc0b63a6449933277725d0088026e3dfac
88 rdf:type schema:PropertyValue
89 N47e6b79e5b66434d9b14129f142da236 rdf:first Ncd02d1d4dec144f1aed04e6d262cd049
90 rdf:rest N293b5ded07854d728c4eadbd35efa5f9
91 N570373fa147f4445a06f290bda7d85a9 schema:name National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
92 rdf:type schema:Organization
93 N575233adaa92435f99ed8e95957e6313 schema:name National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
94 rdf:type schema:Organization
95 N5cd178ac354f464fb0e47f9a3be2e7e3 schema:name National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
96 rdf:type schema:Organization
97 N6177f8f4e20046dcb28b58cf046fcff6 schema:name dimensions_id
98 schema:value pub.1112703658
99 rdf:type schema:PropertyValue
100 N8d6c20535e4c4263bd49b515d51d64f5 rdf:first N9fcf1115ba1d41b4841d9d693454f195
101 rdf:rest N96ef50803b384de3a811da08f1f0b8df
102 N96ef50803b384de3a811da08f1f0b8df rdf:first N242bb738184d4e7f85aadaacbd2248ee
103 rdf:rest rdf:nil
104 N9a1583322c1245f5a287613c22329e91 rdf:first N1935e24362034f7e8519c45a496342a3
105 rdf:rest Ndd44c90335f44f2c84eb8e697a807bd9
106 N9fcf1115ba1d41b4841d9d693454f195 schema:affiliation N570373fa147f4445a06f290bda7d85a9
107 schema:familyName Adeyeye
108 schema:givenName Mojisola Christianah
109 rdf:type schema:Person
110 Ncd02d1d4dec144f1aed04e6d262cd049 schema:affiliation N575233adaa92435f99ed8e95957e6313
111 schema:familyName Ogar
112 schema:givenName Comfort Kunak
113 rdf:type schema:Person
114 Ndcb1880a20b544c3921b7e44a2c90ff2 schema:affiliation N5cd178ac354f464fb0e47f9a3be2e7e3
115 schema:familyName Ibrahim
116 schema:givenName Ali
117 rdf:type schema:Person
118 Ndd44c90335f44f2c84eb8e697a807bd9 rdf:first Ndcb1880a20b544c3921b7e44a2c90ff2
119 rdf:rest N2fb8dc48daf244aba1c1a50d1ba91d28
120 Nf41c0131b0f54a74b96fb3bceee46717 schema:affiliation N2743f016e6254e1796e23a59d551578d
121 schema:familyName Amadi
122 schema:givenName Emmanuel C.
123 rdf:type schema:Person
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
128 schema:name Public Health and Health Services
129 rdf:type schema:DefinedTerm
130 sg:journal.1319803 schema:issn 1178-2595
131 1179-1993
132 schema:name Pharmaceutical Medicine
133 rdf:type schema:Periodical
134 sg:pub.10.1007/bf03262002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021544500
135 https://doi.org/10.1007/bf03262002
136 rdf:type schema:CreativeWork
137 sg:pub.10.1007/s40290-018-0228-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101363171
138 https://doi.org/10.1007/s40290-018-0228-8
139 rdf:type schema:CreativeWork
140 sg:pub.10.1007/s40290-018-0253-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109992161
141 https://doi.org/10.1007/s40290-018-0253-7
142 rdf:type schema:CreativeWork
143 sg:pub.10.1186/1472-6904-9-14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047421326
144 https://doi.org/10.1186/1472-6904-9-14
145 rdf:type schema:CreativeWork
146 sg:pub.10.2165/00002018-200629050-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012106416
147 https://doi.org/10.2165/00002018-200629050-00003
148 rdf:type schema:CreativeWork
149 sg:pub.10.2165/00002018-200932010-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042490964
150 https://doi.org/10.2165/00002018-200932010-00002
151 rdf:type schema:CreativeWork
152 https://app.dimensions.ai/details/publication/pub.1074794042 schema:CreativeWork
153 https://app.dimensions.ai/details/publication/pub.1077250542 schema:CreativeWork
154 https://doi.org/10.1001/jama.279.15.1200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018359649
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1002/prp2.297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083825048
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/j.amjopharm.2006.03.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027174345
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.phrs.2006.05.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038037726
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/s0140-6736(00)02799-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026617336
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1080/20469047.2015.1122384 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025047465
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1111/j.1365-2125.2007.02993.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037610415
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1136/bjo.77.5.315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046282706
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1177/2325957414557264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023283344
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1371/journal.pone.0004439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010384750
173 rdf:type schema:CreativeWork
174 https://doi.org/10.18203/2320-6012.ijrms20180310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100663071
175 rdf:type schema:CreativeWork
176 https://doi.org/10.3233/jrs-160669 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003989029
177 rdf:type schema:CreativeWork
178 https://doi.org/10.4102/sajhivmed.v16i1.305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072231303
179 rdf:type schema:CreativeWork
180 https://doi.org/10.4103/0253-7613.150344 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045701194
181 rdf:type schema:CreativeWork
182 https://doi.org/10.4103/0976-500x.162004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050192219
183 rdf:type schema:CreativeWork
184 https://doi.org/10.4103/2229-3485.111784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020050873
185 rdf:type schema:CreativeWork
186 https://doi.org/10.4103/2229-3485.192044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047448481
187 rdf:type schema:CreativeWork
188 https://doi.org/10.4172/2167-0870.1000155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051379799
189 rdf:type schema:CreativeWork
190 https://doi.org/10.4314/gmj.v48i4.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034395355
191 rdf:type schema:CreativeWork
192 https://doi.org/10.7326/0003-4819-114-4-297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073695304
193 rdf:type schema:CreativeWork
194 https://www.grid.ac/institutes/grid.411276.7 schema:alternateName Lagos State University
195 schema:name Pharmacology, Therapeutic and Toxicology Department, Lagos State University College of Medicine, Lagos, Nigeria
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.411782.9 schema:alternateName University of Lagos
198 schema:name University of Lagos, Lagos, Nigeria
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...